A cardiologist’s recent post on Instagram is racking up tons of views and comments for its major revelation about heart ...

Patients taking Kerendia saw significant reduction in cardiovascular death and hospitalization and urgent visits for heart ...

The drug is now approved for treating people with an LVEF of at least 40%, with or without chronic kidney disease.

With the help of artificial intelligence (AI), an inexpensive test found in many doctors' offices may soon be used to screen ...

The FDA expanded the indication for finerenone (Kerendia) in heart failure (HF), drug manufacturer Bayer announced.

The approval was supported by data from the randomized, double-blind, placebo-controlled, event-driven phase 3 FINEARTS-HF study.

Cardiovascular disease moves in stealth. Years pass with no visible signs. Once chest pain, fatigue or other physical symptoms set in, the heart has already been overworked and damaged. Warning signs ...

Key Takeaways CMS has proposed a mandatory two-sided risk model for specialists treating heart failure and low back pain in outpatient settings. The Ambulatory Specialty Model (ASM) would begin ...

An artificial intelligence model developed by Mayo Clinic and Ultromics accurately screens for cardiac amyloidosis using a ...

Following priority review, the U.S. Food and Drug Administration approved Bayer's Kerendia (finerenone) for the treatment of ...

Discover how MemorialCare's Women's Heart Center at Long Beach is tackling the leading killer of women, heart disease, ...

The use of SGLT2 inhibitors has been a game-changer in the treatment of heart failure (HF). Now, another drug class has ...